Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

Biomarker Research

Laurence de Leval¹  Jacqueline Schoumans²  Françoise Solly³  Sabine Blum⁴  Sophie Voruz⁵  Olivier Spertini⁶ 

[1] Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland;Oncogenomics laboratory, Lausanne University Hospital (CHUV), Lausanne, Switzerland;Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), Lausanne, Switzerland;Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), Lausanne, Switzerland;Lausanne University (UNIL), Lausanne, Switzerland;Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), Lausanne, Switzerland;Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH-1011, Lausanne, Switzerland;Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), Lausanne, Switzerland;Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH-1011, Lausanne, Switzerland;Lausanne University (UNIL), Lausanne, Switzerland;

关键词: Relapsed/refractory B-cell precursor acute lymphoblastic leukemia;    Adult B-cell lymphoma/leukemia;    Targeted treatment;    Chemotherapy regimen;    Daratumumab;    CD38;    venetoclax;    Bcl-2;    Refractory disease;    Immunotherapies;   

DOI  :  10.1186/s40364-021-00343-3

来源: Springer

【 摘 要 】

Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often required to obtain a sustained leukemia-free survival after allogeneic hematopoietic stem cell transplantation. Immunotherapies targeting CD19, CD20, or CD22 are very efficient in achieving this goal. However, in the absence of the expression of these immunotherapeutic targets by lymphoblasts, treatment options are extremely scarce. We report the successful treatment of a 26-year-old man who suffered R/R, CD19, CD20, and CD22 negative B-ALL targeting Bcl-2 and CD38 by combining venetoclax and daratumumab with chemotherapy.

【 授权许可】

CC BY